Q-omics provides the consensus-scored MIR126 profile across patient tissues and cancer cell-line models. MIR126 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR126 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MIR126 RNA expression shows 11,849 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KICH, and THYM as cancer lineages where MIR126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR126 survival associations across molecular data types. MIR126 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR126 RNA expression–survival associations across cancer types. High MIR126 expression shows unfavorable associations in MESO, UCEC, COAD, UVM and PRAD, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR126 RNA expression.
This table summarizes MIR126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR126 shows lower tumor expression in KICH, LUSC, UCEC, LUAD and BRCA and higher tumor expression in KIRC. The KICH box plot shows higher MIR126 RNA expression in normal versus tumor tissue (log2 FC = −1.868, t-test p < 0.001).
This table shows molecular features associated with MIR126 in patient tissues and cancer cell lines. In patient samples, MIR126 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
